Chad J. Creighton

Chad J. Creighton

Top Cited Scholar 2025
Auto-generated profile, based on publicly available information

Chad J. Creighton

Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, USA

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 January 2022 in Neoplasia
Verified
Journal Article
Open access
DCDarshan Shimoga Chandrashekar
Darshan Shimoga Chandrashekar
SKSanthosh Kumar Karthikeyan
Santhosh Kumar Karthikeyan
PKPraveen Kumar Korla
Praveen Kumar Korla
HPHenalben Patel
Henalben Patel
ASAhmedur Rahman Shovon
Ahmedur Rahman Shovon
Sooryanarayana VaramballySooryanarayana Varambally
Sooryanarayana Varambally
Cancer genomic, transcriptomic, and proteomic profiling has generated extensive data that necessitate the development of tools for its analysis and dissemination. We developed UALCAN to provide a portal for easy exploring, analyzing, and visualizing these data, allowing users to integrate the data to better understand the gene, proteins, and pathways perturbed in cancer and make discoveries. UALCAN web portal enables analyzing and delivering cancer transcriptome, proteomics, and patient survival data to the cancer research community. With data obtained from The Cancer Genome Atlas (TCGA) project, UALCAN has enabled users to evaluate protein-coding gene expression and its impact on patient survival across 33 types of cancers. The web portal has been used extensively since its release and received immense popularity, underlined by its usage from cancer researchers in more than 100 countries. The present manuscript highlights the task we have undertaken and updates that we have made to UALCAN since its release in 2017. Extensive user feedback motivated us to expand the resource by including data on a) microRNAs (miRNAs), long non-coding RNAs (lncRNAs), and promoter DNA methylation from TCGA and b) mass spectrometry-based proteomics from the Clinical Proteomic Tumor Analysis Consortium (CPTAC). UALCAN provides easy access to pre-computed, tumor subgroup-based gene/protein expression, promoter DNA methylation status, and Kaplan-Meier survival analyses. It also provides new visualization features to comprehend and integrate observations and aids in generating hypotheses for testing. UALCAN is accessible at http://ualcan.path.uab.edu

1 September 2014 in Cancer Cell
Verified
Journal Article
Closed access
CDCaleb F. Davis
Caleb F. Davis
CRChristopher J. Ricketts
Christopher J. Ricketts
MWMin Wang
Min Wang
ACAndrew D. Cherniack
Andrew D. Cherniack
HSHui Shen
Hui Shen
HSHeidi J. Sofia
Heidi J. Sofia

1 June 2017 in Cancer Cell
Verified
Journal Article
Closed access
YZYiqun Zhang
Yiqun Zhang
PNPatrick Kwok-Shing Ng
Patrick Kwok-Shing Ng
MKMelanie Kucherlapati
Melanie Kucherlapati
FCFengju Chen
Fengju Chen
YLYuexin Liu
Yuexin Liu
CCChad J. Creighton
Chad J. Creighton

6 February 2017 in Nature Neuroscience
Verified
Journal Article
Closed access
PDF file
CLChia-Ching John Lin
Chia-Ching John Lin
KYKwanha Yu
Kwanha Yu
AHAsante Hatcher
Asante Hatcher
THTeng-Wei Huang
Teng-Wei Huang
HLHyun Kyoung Lee
Hyun Kyoung Lee
BDBenjamin Deneen
Benjamin Deneen

12 December 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
FCFengju Chen
Fengju Chen
DCDarshan S. Chandrashekar
Darshan S. Chandrashekar
SVSooryanarayana Varambally
Sooryanarayana Varambally
CCChad J. Creighton
Chad J. Creighton
Mass-spectrometry-based proteomic profiling of human cancers has the potential for pan-cancer analyses to identify molecular subtypes and associated pathway features that might be otherwise missed using transcriptomics. Here, we classify 532 cancers, representing six tissue-based types (breast, colon, ovarian, renal, uterine), into ten proteome-based, pan-cancer subtypes that cut across tumor lineages. The proteome-based subtypes are observable in external cancer proteomic datasets surveyed. Gene signatures of oncogenic or metabolic pathways can further distinguish between the subtypes. Two distinct subtypes both involve the immune system, one associated with the adaptive immune response and T-cell activation, and the other associated with the humoral immune response. Two additional subtypes each involve the tumor stroma, one of these including the collagen VI interacting network. Three additional proteome-based subtypes—respectively involving proteins related to Golgi apparatus, hemoglobin complex, and endoplasmic reticulum—were not reflected in previous transcriptomics analyses. A data portal is available at UALCAN website.

5 February 2020 in Nature Genetics
Verified
Journal Article
Open access
PDF file
YYYuan Yuan
Yuan Yuan
YJYoung Seok Ju
Young Seok Ju
DKDongik Kim
Dongik Kim
JLJun Li
Jun Li
YWYumeng Wang
Yumeng Wang
HLHan Liang
Han Liang
Mitochondria are essential cellular organelles that play critical roles in cancer. Here, as part of the International Cancer Genome Consortium/The Cancer Genome Atlas Pan-Cancer Analysis of Whole Genomes Consortium, which aggregated whole-genome sequencing data from 2,658 cancers across 38 tumor types, we performed a multidimensional, integrated characterization of mitochondrial genomes and related RNA sequencing data. Our analysis presents the most definitive mutational landscape of mitochondrial genomes and identifies several hypermutated cases. Truncating mutations are markedly enriched in kidney, colorectal and thyroid cancers, suggesting oncogenic effects with the activation of signaling pathways. We find frequent somatic nuclear transfers of mitochondrial DNA, some of which disrupt therapeutic target genes. Mitochondrial copy number varies greatly within and across cancers and correlates with clinical variables. Co-expression analysis highlights the function of mitochondrial genes in oxidative phosphorylation, DNA repair and the cell cycle, and shows their connections with clinically actionable genes. Our study lays a foundation for translating mitochondrial biology into clinical applications.